GlassScriptPhysician profile
Douglas J Hess
NPI 1679864441
$9,640.71
in general payments reported to CMS, 2019-2025
18 companies · $779 in 2025
The $779 reported for 2025 was more than what 82% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,445 · 2020: $2,817 · 2021: $920 · 2022: $48.18 · 2024: $632 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $8,072.40 | 2019-2021 | |
| Axsome Therapeutics, INC. | $263.75 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $245.80 | 2024-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $149.09 | 2019-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.40 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $121.60 | 2025 | Cobenfy |
| Abbvie INC. | $114.01 | 2022-2025 | |
| Neuronetics, INC. | $112.79 | 2024 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $60.69 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $59.53 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $55.15 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $54.68 | 2024 | Qelbree |
| Sage Therapeutics, LLC | $45.61 | 2024 | |
| Ironshore Pharmaceuticals INC. | $43.79 | 2024 | |
| Janssen Scientific Affairs, LLC | $33.31 | 2025 | Invega Sustenna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.24 | 2025 | Jornay Pm |
| Novo Nordisk INC | $23.24 | 2025 | Wegovy |
| Vanda Pharmaceuticals INC. | $21.63 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.